Displaying 38 (all) recruiting clinical trials.
-
A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect ...
-
AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
The purpose of this study is to test the safety of mosunetuzumab at different dose levels when given in combination with polatuzumab vedotin and to ... -
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ... -
A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
The purpose of this study is to test the safety and to define the appropriate dose of an investigational drug (CC-220) and an investigational combination ... -
A Phase 1b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer
The purpose of the study is to determine the safety and efficacy of the treatments: AB928, a novel adenosine receptor blocker, plus zimberelimab, an anti-PD1 ... -
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ... -
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug ... -
A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
The purpose of the study is to determine the side effects and best dose of anetumab ravtansine when given together with nivolumab, ipilimumab and gemcitabine ... -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
The purpose of the study is to determine if M3814 in combination with radiation therapy and avelumab is safe and tolerable in patients with advanced ... -
A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant hormone receptor positive HER2 negative metastatic breast cancer (FAC vs FA)
The purpose of the study is to determine the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in ...